The Oklahoma Supreme Court Gave a Bizarre Explanation for Restricting the Abortion Pill

<a href="">Ivanko80</a>/Shutterstock

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

The Oklahoma Supreme Court on Tuesday upheld restrictions on the abortion pill, but the justices also noted that “by the state’s own evidentiary materials, more restrictions on abortions result in higher complication rates and in decreased women’s safety.”

Since the Food and Drug Administration gave its approval to mifepristone—a.k.a. the abortion pill—in 2000, more than 2 million women have ended their pregnancies using medication alone. The law in question, which went into effect in 2014, requires physicians to abide by a decade-old FDA protocol when administering abortion medication. That protocol includes high dosages of abortion drugs (mifepristone is one of two drugs used) and three visits to the doctor’s office—requirements that medical experts describe as unnecessary, as well as less effective and more expensive than the off-label use of these drugs. The FDA protocol also makes the medication harder to tolerate—failure rates more than double compared with those from off-label use, and almost every woman experiences at least one severe side effect like nausea, vomiting, or cramps.

That’s why, when prescribing abortion medication, over 80 percent of physicians follow an off-label method, developed by medical organizations such as the American College of Obstetricians and Gynecologists and supported by the World Health Organization. That regimen has fewer side effects and a lower failure rate than the FDA method. And it can be used later in pregnancy: Physicians typically prescribe abortion drugs until the ninth week of pregnancy, while the FDA regimen can only be used until the seventh week.

Abortion rights groups, including the Center for Reproductive Rights and the Oklahoma Coalition for Reproductive Justice, sued Oklahoma in 2014, arguing that the law ignores medical evidence and harms women.

The court on Tuesday ultimately upheld the law and ruled that it doesn’t violate the constitution, even though it’s bad public health. And one justice, Douglas Combs, wrote an opinion in which he concurred with the court but questioned the law.

“Once again, those who do not practice medicine have determined to insert themselves between physicians and their patients, with the insistence they know what is best when it comes to the standard of care,” wrote Combs. “The medical community should take heed: now that the Legislature has declared itself willing to dictate medical protocol and practice within this limited context, what areas of the practice of medicine are next?”


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend